Establishment Labs Revenue Surges 31.7% Driven by U.S. Market Expansion

Key Facts

1Establishment Labs achieved 31.7% revenue growth in Q2 2026.

2Gross margins expanded to 70.6% driven by U.S. market entry.

3U.S. sales accounted for 89% of the company's total growth.

In a move reflecting successful global expansion within the medical device sector, Establishment Labs reported strong financial results for the second quarter of 2026. The company achieved revenue growth of 31.7%, primarily driven by its strategic entry into the U.S. market following regulatory approvals. According to reports, U.S. sales accounted for a substantial 89% of the company's total growth during this period.

Profitability metrics showed significant improvement as gross margins expanded to 70.6%, which analysts attribute to the launch of high-margin offerings like Preservé in the U.S. market. These results stem from the company's ability to generate higher revenue per procedure compared to traditional methods. Per market data, this performance strengthens the company's financial position relative to peers in the medical aesthetics industry.

Looking ahead, markets are watching for the sustainability of this momentum, though specific price levels for ESTA remain unavailable (close September 9, 2026). With Canadian interest rates holding at 2.25% and recent U.S. economic data showing mixed signals—such as factory orders rising 0.9%—investors remain focused on how macroeconomic conditions will influence consumer spending on elective procedures in the coming quarter.